Stocktoria
Roivant Sciences Ltd. ROIV
Roivant Sciences Ltd. (ROIV) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2026 revenue was $8.3M at a -3629.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-10 | Citigroup | Buy (main) |
| 2026-08-07 | Guggenheim | Buy (main) |
| 2026-08-07 | HC Wainwright & Co. | Buy (main) |
| 2026-05-26 | Guggenheim | Buy (main) |
| 2026-05-21 | Citigroup | Buy (main) |
| 2026-05-21 | TD Cowen | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.856 |
| Retained earnings / assets | -0.088 |
| EBIT / assets | -0.09 |
| Equity / liabilities | 12.714 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ROIV | Roivant Sciences Ltd. | 1/9 | 18.07 | — | -71.6% |
| COYA | Coya Therapeutics, Inc. | 2/9 | 5.24 | — | — |
| ACRS | Aclaris Therapeutics, Inc. | 2/9 | -18.21 | — | -58.2% |
| CRNX | Crinetics Pharmaceuticals, Inc. | 2/9 | 6.19 | — | — |
| ADAG | Adagene Inc. | 4/9 | -9.75 | — | — |
| XENE | Xenon Pharmaceuticals Inc. | 2/9 | 6.89 | — | — |
| OVID | Ovid Therapeutics Inc. | 1/9 | 0.8 | — | -96.8% |
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
FAQ
Is ROIV financially healthy?
Roivant Sciences Ltd.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ROIV pay a dividend?
No, Roivant Sciences Ltd. does not currently pay a dividend.
How profitable is ROIV?
In FY2026, Roivant Sciences Ltd. had a net margin of -3629.2% and a return on equity of -5.7%.
What is the analyst price target for ROIV?
The average Wall-Street price target for Roivant Sciences Ltd. is $41.82, about 15.6% above the recent price, from 11 analysts (consensus: strong buy).
Is ROIV a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Roivant Sciences Ltd.: a Piotroski F-score of 1/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.